NPCE - יחס חוב להיוון בספרים NeuroPace Inc

NeuroPace, Inc. (NPCE) develops an advanced neurostimulator that functions as a pacemaker for the brain, treating epilepsy through continuous activity analysis. Profit growth is driven by the expansion of the implant network and service maintenance, which reduces R&D costs. Success is based on physician adoption of the method and insurance reimbursements, with the indicator standing at 5.81. This chart of current share prices confirms these fundamental theses.

This indicator assesses the total liabilities-to-equity ratio, determining the company's reliance on external financing and its overall financial stability. The current value of 5.81 within the historical debt-to-capitalization metrics allows investors to evaluate the leverage risk of NeuroPace, Inc. (NPCE) as it scales the RNS system in the neuromodulation market for refractory epilepsy therapy.